Find recruiting clinical trials for prostate cancer in the UK � from localised disease through hormone-sensitive to castration-resistant (CRPC). See your treatment pathway and where trials fit in.
Free to use � Live data from ClinicalTrials.gov � Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Cancer confined to the prostate gland
Standard: Surgery (prostatectomy), radiation therapy, or active surveillance
Cancer has spread but still responds to hormone therapy
Standard: ADT + ARPI (Apalutamide, Enzalutamide, or Abiraterone)
Cancer progressing despite hormone therapy
Standard: ARPI switch, Docetaxel chemotherapy, or Radium-223 (bone mets)
After chemotherapy � clinical trials are especially important
Standard: Cabazitaxel, PARP inhibitor (if BRCA/HRR mutation), Lu-177-PSMA, or clinical trial
Prostate-Specific Antigen is the primary marker for monitoring disease progression and treatment response. Rising PSA often precedes visible progression on scans.
About 10-15% of metastatic prostate cancers have homologous recombination repair gene mutations. These patients may benefit from PARP inhibitors like olaparib or rucaparib.
Prostate-Specific Membrane Antigen is expressed on most prostate cancer cells. PSMA-targeted therapies like Lu-177-PSMA-617 represent a major advance in advanced disease.
Loading trials from ClinicalTrials.gov...
Active research includes PARP inhibitors (Olaparib, Rucaparib) for BRCA-mutant disease, PSMA-targeted therapy (Pluvicto/Lutetium-177), novel androgen receptor inhibitors, radioligand therapy, and immunotherapy combinations.
PSMA (prostate-specific membrane antigen) therapy delivers radiation directly to prostate cancer cells. Lutetium-177 PSMA (Pluvicto) is approved for advanced disease. Trials are studying earlier use and next-generation PSMA agents.
Yes. Active surveillance trials study the safety of monitoring versus immediate treatment, test new imaging techniques (PSMA PET), and investigate markers that predict which cancers will become aggressive.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.